Cynity is an advanced biotechnology company focused on developing innovative proprietary drugs and therapies in regenerative medicine designed to enhance and extend the quality of life of our patients.
We focus our research and development on different types of human cells: adipose derived and umbilical cord derived mesenchymal stem cells cultured using a totally animal origin free medium proprietary medium.
We also conduct research on progenitor cells using cells from several types of human vital organs.
Cynity is preparing several clinical trial programs in collaboration with medical universities and clinical institutions across Japan and the US.
We are making a substantial investment in a dedicated building in central Tokyo that will be one of Japan’s first fully integrated regenerative medicine complex.
The new complex includes cell processing facilities, research & development center, contracted clinic and medical support facilities.